Free Trial
NYSE:NUVB

Nuvation Bio Q1 2024 Earnings Report

Nuvation Bio logo
$2.19 -0.05 (-2.23%)
Closing price 03:59 PM Eastern
Extended Trading
$2.22 +0.04 (+1.60%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvation Bio EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Nuvation Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvation Bio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Nuvation Bio's Q2 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nuvation Bio Earnings Headlines

“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
See More Nuvation Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email.

About Nuvation Bio

Nuvation Bio (NYSE:NUVB), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

View Nuvation Bio Profile

More Earnings Resources from MarketBeat